

SERUM APELIN IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DM: RELATION TO GLUCOSE METABOLISM AND INSULIN SENSITIVITY

Thesis

In partial fulfillment of masters degree in pediatrics

Presented by

Nehal Refat Abdel Aleem

M.B.B.Ch. 2008, Faculty of Medicine, Ain Shams University

Supervised by

Prof. Dr. Mona Hussein El Samahy

Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Dr. Abeer Ahmed Abd Elmaksoud

Assistant Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Dr. Dina Elsayed Elshennawy

Lecturer Professor of Pediatrics

Faculty of Medicine, Ain Shams University

Faculty of Medicine, Ain Shams University

2014



Acknowledgement

Thanks to **ALLAH** Who helped me to accomplish this work

My deepest and warmest gratitude to my great supervisor Professor Mona Hussein Elsamahy, Professor of Pediatrics, faculty of Medicine, Ain Shams University, Who in addition to her valuable guidance and supervision, has provided me with a great deal of support, encouragement and knowledge

I would like to express my great appreciation and thanks to Doctor Abeer Ahmed Abd El Maksoud, Assistant Professor of Pediatrics, faculty of medicine, Ain Shams University. It was an honor to me to carry out this work under her continuous guidance, and supervision encouragement and expert supervision.

The present work could not have been done without the help of Doctor Dina Elsayed Elshenawy, Lecturer of Clinical pathology, Faculty of medicine Ain Shams University, for hr guidance and continuous support.

Contents

Introduction	1
Aim of the Work.....	4
Review of Literature	
▪ chapter (1): Diabetes mellitus	5
▪ chapter 92): the apelinergic system	35
▪ Chapter (3): Apelin	56
Patients and Methods	72
Results	80
Discussion	107
Summary.....	121
Conclusion.....	125
Recommendations	126
References	127
Arabic Sumary	

List of Tables

Table No.	Title	Page No.
Table (1):	Characteristic features of type 1 compared with type 2 diabetes in yougn people	5
Table (2):	The clincial and biological characteristics of the differetn subtypes of type 1 diabetes.	10
Table (3):	Complications of type 1 diabetes	34
Table (4):	Age distribution among controlled, uncontrolled diabetic and control groups	80
Table (5):	Sex distribution among controlled, uncontrolled diabetic and control groups	82
Table (6):	Antrhopometric measures didfferences among controlled, uncontrolled diabetic and control groups	83
Table (7):	Age at diagnosis and duration of diabets among controlled and uncontrolled diabetic groups	85
Table (8):	Incidence of complciations among controlled and uncontrolled diabetic groups	87
Table (9):	Demonstrating vital data measurements among controlled, uncontrolled diabetic and control groups.	89
Table (10):	comparison between controlled, uncontrolled diabetic and control groups as regards lipid profile	91

Table (11):	Comparison between controlled uncontrolled diabetic and control groups as regards lab investigations.....	94
Table (12):	comparison between controlled, uncontrolled diabetic and control groups as regards serum aplin level	96
Table (13):	Correlation between apelin level and various variables in the three studied groups	98
Table (14):	comparison of various variables in patients with HOMA-IR ≤ 3.16 and those with HOMA-IR > 3.16	100
Table (15):	ROC curve analysis for prediction of diabetes usign apelin level	101
Table (16):	ROC curve analysis for predictionof the status of disease control using apelin level	103
Table (17):	ROC curve analsysis for prediction of HOMA-IR > 3.16 using serum apelin level.....	105

List of Figures

Fig. No.	Title	Page No.
Figure (1):	reported "Small molecule" APJ agonist.....	38
Figure (2):	Intacellular pathways responsible for positive inotropic effect of the apelin/APJ interaction	42
Figure (3):	Intracellular pathways responsible for the vasomotor effects in the apelin/APJ interaction in the absence and in the presence of endothelial dysfunction	46
Figure (4):	Adipose tissue releases several adipokines	61
Figure (5):	immunostaining for apelin	71
Figure (6):	Age distribution among controlled, uncontrolled diabetic and control groups	81
Figure (7):	Sex distribution among controlled, uncontrolled diabetic and control groups	82
Figure (8):	Body mass index among controlled, uncontrolled diabetic and control groups	84
Figure (9):	Showing age at diagnosis of diabetes among controlled and uncontrolled diabetic groups	85
Figure (10):	Showing duration of diabetes among controlled and uncontrolled diabetic groups	86
Figure (11):	Showing daily insulin dose among controlled and uncontrolled diabetic groups	86
Figure (12):	Showing incidence of complications among controlled and uncontrolled diabetic groups	88
Figure (13):	Heart rate among controlled, uncontrolled diabetic and control groups	90
Figure (14):	Blood pressure among controlled, uncontrolled diabetic and control groups	90
Figure (15):	HDL among controlled, uncontrolled diabetic and control groups.....	92
Figure (16):	HDL among controlled, uncontrolled diabetic and control groups.....	92
Figure (17):	Triglyceride among controlled, uncontrolled diabetic and control groups.....	93
Figure (18):	Total cholesterol among controlled, uncontrolled diabetic and control groups	93

Figure (19):	Fasting blood glucose showing HbA1 C among controleld and uncontrolled diabetic groups.....	95
Figure (20):	Showing HbA1c among controlled and uncontrolled diabetic groups	95
Figure (21):	Serum apelin level among controlled, uncontroled diabetic and control groups	97
Figure (22):	ROC curve for prediction of disease status using serum apelin level	102
Figure (23):	ROC curve for prediction of the status of disease control using serum apelin level	104
Figure (24):	ROC curve for prediction of HOMA-IR > 3.6 using serum apelin level	106

List of Abbreviations

AA	Aminoacids
ACE2	Angiotensin converting enzyme 2
ACTH	Adrenocorticotrophic hormone
ADA	American Diabetes Association
Ang II	Angiotensin II
APJ	Apelin recpeotr
AT-1	Angiotensin II type 1 receptor
AUC	Areas under the curve
BMI	Body mass index
cGMP	Cyclic guanosine monophosphate
CNS	Central nervous system
CVD	Cardiovascular disease
DAG	Diacylglycerol
DIAMOND	Diabetes mondiale
DM	Diabetes mellitus
eNOS	Endothelial nitric oxide Synthase
ERKs	Extracellular regulated kinases
EURODIAB	European diabetes
FSH	Follicle stimulating hormone
GPCRs	G protein-coupled membrane receptors
h	Hour
HO	Null hypothesis

HbA1c	Glycosylated Hemoglobin
HF	heart failure
HLA	Human Leucocytic Antigen
HOMA-IR	Homeostatic model assessment- insulin resistance
IDDM	insulin-dependent diabetes mellitus
IL	interleukin
kg	kilogram
LADA	latent auto-immune diabetes of adult
LH	luteinizing hormone
MCP	monocyte chemo-attractant protein
MHC	major histocompatibility complex
ml	milliliter
NCX	Na ⁺ -Ca ²⁺ exchanger
ng	nanogram
NHE	Na ⁺ -H ⁺ exchanger
NO	nitric oxide
PCR	polymerase chain reaction
PI3K	Phosphoinositide 3-kinase
PKC	Protein Kinase C
PLC	phospholipase C
P _{max}	Maximum pressure
pmol	pico mole
PTX	pertussis toxin

SNPs	Single nucleotide polymorphisms
T1D	Type 1 diabetes
T2D	Diabetes mellitus type 2
Th	T helper cell
TNF α	Tumor necrosis factor - α

Introduction

Diabetes Mellitus (DM) is group of metabolic diseases characterized by hyperglycemia resulting from defect in insulin secretion, insulin action, or both (*American Diabetes Association, 2007*).

Apelin, a recently described adipocytokine, is abundantly expressed in adipose tissue and produced in the endothelial cells in various parts of the body (*Kleinz et al., 2004*).

Plasma apelin levels were reported to increase in obesity in association with hyperinsulinemia (*Boucher et al., 2005*).

The first evidence of an involvement of apelin on insulin secretion came from the study of Sorhede Winzell et al. showing that apelin inhibits insulin secretion stimulated by glucose in vivo in mice and in vitro in isolated islets of Langerhans (*Sorhede Winzell et al., 2005*).

Apelin was also shown to stimulate glucose transport in an AMPK-dependent manner in human adipose tissue (*Attane et al., 2011*). Moreover, in insulin-resistant 3T3-L1 adipocytes (due to TNF α treatment for 24 h), insulin-stimulated glucose uptake was reduced by 47%, whereas apelin treatment resulted in an increased glucose uptake through the PI3K/Akt pathway and improved insulin-stimulated glucose uptake (*Zhu et al., 2011*).

Intravenous apelin administration at low concentration (200 pmol/kg) decreased blood glucose in mice and improved glucose (*Dray et al., 2008*).

Furthermore during an hyperinsulinemic-euglycemic clamp, when the hepatic glucose production is totally inhibited, apelin increases glucose utilization throughout the entire organism mainly due to a rise in glucose uptake by skeletal muscles and adipose tissues. In isolated skeletal muscle (soleus), apelin stimulates glucose transport and its effect is additive to that of insulin (*Dray et al., 2008*).

The role of central apelin on glucose metabolism has been recently studied in our group. Acute intracerebroventricular. apelin has differential effect depending of the injected dose and the nutritional status. Acute low-dose of intracerebroventricular. apelin injection decreased peripheral fed glycemia, increased glucose and insulin tolerance in mice via a NO signaling pathway. All these beneficial actions of i.c.v. apelin on glucose homeostasis were blunted in HFD obese/diabetic mice. As the opposite, acute high-dose of intracerebroventricular. apelin injection provoked fasted hyperglycemia/hyperinsulinemia and decreased insulin sensitivity in normal mice (*Duparc et al., 2011*).

Aim of the work

To evaluate Serum apelin level in children and adolescent with type 1 diabetes mellitus and its relation to glycemic control, lipid metabolism and markers of insulin sensitivity.

Diabetes Mellitus

Definition

Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia resulting from defect in insulin secretion, action, or both (*ADA, 2007*).

DM is not a simple disease but it is a heterogeneous group of disorders in which there are distinct genetic pattern of inheritance as well as separate etiologic and physiologic mechanisms all leading to impairment of glucose metabolism (*Gabir et al., 2000*).

Systemic vascular dysfunction is a central part of the pathophysiology of both type I insulin dependent and type II non insulin dependent coronary heart disease is the leading cause of morbidity and mortality in diabetes and account for 60% of death in this group peripheral vascular disease, retinopathy and nephropathy are all more common in diabetes and lead to significant morbidity (*Schallcwijlc et al., 2005*).

The development and progression of diabetic complications are strongly related to the degree of glycemic control (*Ozmen and Boyuada, 2003*).

Classification

Etiologic classification of diabetes mellitus *American diabetes Association (ADA, 2007)*

I. Type 1 β -cell destruction, usually leading to absolute insulin deficiency <ol style="list-style-type: none">AutoimmuneIdiopathic	
II. Type 2 May range from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with or without insulin resistance	
III. Other specific types	
A. Mongenic defects of β -cell function <ol style="list-style-type: none">HNF-1α MODY (MODY 3),Glucokinase MODY (MODY 2)HNF-4 α MODY (MODY 1),HNF-1B MODY (MODY 4)WFS1 Wolfram syndromeNeonatal diabetesOther MODY	F. Drug- or chemical-induced <ol style="list-style-type: none">GlucocorticoidsVacorPentamidineNicotinic acidThyroid hormoneDiazoxideβ-adrenergic agonistsThiazidesDilantinα -InterferonOthers
B. Mitochondrial diabetes	
C. Genetic defects in insulin action <ol style="list-style-type: none">Type A insulin resistanceLeprechaunismRabson-Mendenhall syndromeLipoatrophic diabetesOthers	G. Infections <ol style="list-style-type: none">Congenital rubellaCytomegalovirusOthers